| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Feb, 2026 | Feb, 2026 |
| Sales | 5,000 | 50,000 | 0 | 0 | 0 |
| Sales Growth | -90.00% | unch | unch | unch | unch |
| Net Income | -156,990 | -37,120 | -119,280 | 0 | 0 |
| Net Income Growth | -322.93% | +68.88% | unch | unch | unch |
Zenas Biopharma Inc
(ZBIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc'RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.
Fiscal Year End Date: 12/31